Structure Therapeutics Inc. (GPCR)

NASDAQ

$64.84

-$2.22 (3.31%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$64.50$68.47

Open $67.08

52 Week Range

$13.22$94.90

Previous Close $67.06

Market Cap3.73B

Volume1.05M

Avg Volume1.47M

P/E (TTM)-6.94

EPS (TTM)$-9.34

Dividend / YieldN/A

Dividend StreakN/A

Latest News for Structure Therapeutics Inc.

DEC11

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met...

globenewswire.com•4 days ago

DEC9

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met...

globenewswire.com•6 days ago

DEC9

GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron

Structure Therapeutics jumps after phase II data show aleniglipron delivering strong, durable weight-loss results across multiple studies....

zacks.com•6 days ago

DEC9

Structure Therapeutics: Phase 2b Puts Aleniglipron In The Oral GLP-1 Top Tier (Rating Upgrade)

Structure Therapeutics (GPCR) delivered robust Phase 2b results for aleniglipron, surpassing key efficacy and tolerability thresholds for oral GLP-1 therapies. GPCR now appears competitive with top or...

seekingalpha.com•6 days ago

DEC8

Why Structure Therapeutics Stock Doubled and Then Some on Monday

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron....

fool.com•7 days ago

DEC8

Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript

Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript...

seekingalpha.com•7 days ago

DEC8

Structure: Maintaining Strong Buy As Aleniglipron Succeeds In Obesity Study Program

Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at...

seekingalpha.com•7 days ago

DEC8

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for met...

globenewswire.com•7 days ago

DEC8

Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points on Monday....

benzinga.com•7 days ago

DEC8

Structure Therapeutics stock: what's driving sudden 103% jump in GPCR shares?

Structure Therapeutics stock (NASDAQ: GPCR) rocketed above 103% Monday, trading near $70, after the clinical-stage biotech released promising mid-stage results for its oral obesity drug, aleniglipron....

invezz.com•7 days ago